Vireo Growth (VREOF) Current Leases (2020 - 2026)
Vireo Growth (VREOF) reported Current Leases of $6.1 million for Q1 2026, up 430.9% on a YoY basis from $1.1 million in Q1 2025, and up 69.44% sequentially from $3.6 million in Q4 2025.
Vireo Growth (VREOF) Current Leases (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Current Leases data on file, last reported at $6.1 million in Q1 2026.
- For the quarter ending Q1 2026, Current Leases rose 430.9% year-over-year to $6.1 million; the trailing twelve-month figure through Mar 2026 stood at $6.1 million (up 430.9% YoY), and the FY2025 full-year result was $3.6 million, up 157.14% from the prior year.
- Current Leases improved to $6.1 million in Q1 2026, from $3.6 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $6.1 million in Q1 2026 to a low of $882457.0 in Q1 2024.
- A 5-year average of $2.1 million and a median of $1.4 million in 2024 frame the typical range for Current Leases.
- Across the five-year window, Current Leases sank 49.97% in 2023 and surged 430.9% in 2026, its largest moves.
- Tracing VREOF's Current Leases over 5 years: stood at $1.7 million in 2022, then plunged by 47.03% to $890013.0 in 2023, then jumped by 57.3% to $1.4 million in 2024, then soared by 157.14% to $3.6 million in 2025, then soared by 69.44% to $6.1 million in 2026.
- Business Quant data shows VREOF's Current Leases at $6.1 million in Q1 2026, $3.6 million in Q4 2025, and $4.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 6.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.10 Mn |
| Dec 31, 2025 | 3.60 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Jun 30, 2025 | 4.35 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | 1.40 Mn |
| Sep 30, 2024 | 1.25 Mn |
| Jun 30, 2024 | 953,389.00 |
| Mar 31, 2024 | 882,457.00 |
| Dec 31, 2023 | 890,013.00 |
| Sep 30, 2023 | 907,998.00 |
| Jun 30, 2023 | 888,327.00 |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | 1.68 Mn |
| Sep 30, 2022 | 1.71 Mn |
| Jun 30, 2022 | 1.78 Mn |
| Mar 31, 2022 | 1.70 Mn |
| Dec 31, 2021 | 1.60 Mn |
| Sep 30, 2021 | 1.40 Mn |
| Jun 30, 2021 | 1.28 Mn |